Disease Site & IND Committees

Queen's University ITS will be performing network maintenance on Saturday, August 19 beginning at 12 am and lasting until approximately 5 am EDT. 

Access to services that are physically housed on campus, such EDC, Mango and the main Canadian Cancer Trials Group website will NOT be available from off campus through the maintenance period.

 
 

Disease site committees discuss proposals for new studies, consider their scientific merit and feasibility, and assign priorities when necessary. Currently, there are 10 disease site committees including brain, breast, lung, gastrointestinal, genitourinary, gynecologic, hematologic, melanoma, sarcoma, and symptom control.

Each disease site committee is composed of representatives from centres participating in Canadian Cancer Trials Group trials whose primary function is to communicate to the Group the attitudes of their centres regarding trial proposals. Therefore, membership of disease site committees is centre-specific and is determined by the Centre Representative. Disease site committee representation is available to centres participating, or planning to participate, in Canadian Cancer Trials Group trials in the site in question. A Centre Representative may nominate up to three members to sit on a site committee to ensure relevant modalities are represented.

Each disease site committee has a chair and an executive. The primary role of the disease site executive committees is to review studies proposed by their respective site committees and, on the basis of that review, to recommend trials for consideration to the Clinical Trials Committee in order of priority.
The IND Committee advises the Director of the IND Program on policy matters and the overall direction of new drug studies, and to that extent serves as an extension of the Clinical Trials Committee and as a standing modality committee. Membership of the IND Committee is largely determined, however, by phase I and II study participation. Members are expected to represent the views of their centres regarding interest and feasibility in proposed studies and serve as conduits for communication within their centres.
The IND Executive Committee acts to provide ongoing review of the specific program goals and priorities, as well as review and approval (or not) of specific trial proposals. The Executive meets in person or by telephone 4-6 times per year. Members of the Executive include the Chair of the IND Committee, Central Office staff, IND investigators, and basic scientists.
Information for the Brain Disease Site Committee meetings.

Go to Committee  

The Breast Disease Site Committee (BDSC) was established in 1984 and is composed of core members from member institutions in Canada representing all modalities of cancer care: medical oncology, radiation oncology, surgery plus other allied professionals from nursing, biostatistics, molecular biology, investigative pathology and patient advocacy. The Committee has several major research priorities: to improve loco regional control and systemic therapy including the incorporation of novel/targeted agents, both in the adjuvant and metastatic setting; to incorporate other endpoints into clinical trials such as Quality of Life and Health Economics; to conduct correlative biology assessments and outcomes.

Go to Committee  

Information for the Gastro-Intestinal Disease Site Committee.

Go to Committee  

Information for the Genito-Urinary Disease Site Committee.

Go to Committee  

Information for the Gynecologic Disease Site Committee.

Go to Committee  

Information for the Head & Neck Working Group.

Go to Committee  

Information for the Hematologic Disease Site Committee.

Go to Committee  

Information for the IND Disease Site Committee.

Go to Committee  

Information for the Lung Disease Site Committee.

Go to Committee  

Information for the Lung CSTB Working Group.

Go to Committee  

Information for the Melanoma Disease Site Committee.

Go to Committee  

Information for the Sarcoma Disease Site Committee.

Go to Committee  

Information for the Symptom Control Disease Site Committee.

Go to Committee